Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1)

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Jeffrey A. Lieberman, T. Scott Stroup, Joseph P. McEvoy et al. · New England Journal of Medicine · 2005 · 5.9K citations · Full text

Medicine, Pharmacotherapy, Psychiatry +14

The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome

Douglas W Heinrichs, Thomas E. Hanlon, William T. Carpenter · Schizophrenia Bulletin · 1984 · 1.7K citations · Full text

Social Sciences, Psychiatry, Psychology +17

Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia

Peter B. Jones, Thomas R. E. Barnes, Linda Davies et al. · Archives of General Psychiatry · 2006 · 1.1K citations

Pharmacy, Pharmacotherapy, Psychiatry +17

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

Gary D. Tollefson, Charles M. Beasley, P.V. Tran et al. · American Journal of Psychiatry · 1997 · 901 citations

Medicine, Pharmacotherapy, Psychiatry +17

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

Thomas R. E. Barnes, Richard Drake, Carol Paton et al. · Journal of Psychopharmacology · 2019 · 596 citations · Full text

Medicine, Pharmacology, Psychiatry +13